While lysine acetyltransferase 6A (KAT6A; MOZ/MYST3) and 6B (KAT6B; MORF/MYST4) function as context-dependent oncogenic drivers—with KAT6B also displaying tissue-specific tumor-suppressive roles—their pharmacological targeting holds promise as a therapeutic avenue. This conceptual and translational review synthesizes e...
Cong Ma, Jing-Ru Wang, Guan-Hua Qiao et al.· Frontiers in Immunology· 0 citations
Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patient...
B. Lan, Faliang Xu, Tao Sun et al.· Signal Transduction and Targ...· 0 citations
The clinical benefit of immunotherapy in breast cancer has moved from metastatic triple-negative breast cancer (TNBC) into earlier-stage high-risk disease, but primary resistance, acquired resistance and non-durable responses remain frequent. Programmed death-ligand 1 (PD-L1), tumour-infiltrating lymphocytes (TILs), tu...
Sen-Yang Guo, Feng Yuan, Yi-Min Qin et al.· International Immunopharmaco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
